Amended Current Report Filing (8-k/a)
31 Agosto 2021 - 4:50PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
Amendment
No. 1
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 27, 2021
REGEN
BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
|
Nevada
|
45-5192997
|
|
(State
or other jurisdiction of incorporation or organization)
|
(I.R.S.
Employer Identification No.)
|
Commission
File No. 333-191725
711
S. Carson Street, Suite 4, Carson City, Nevada, 89791
(Address
of Principal Executive Offices)
(619)
722 5505
(Issuer’s
telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Purpose
of Amendment:
The
phrase
The
Company has not issued debt convertible into equity securities of the Company since July 2020 and does not currently intend to issue
any additional instruments convertible into the equity securities of the Company.
is
corrected to read:
The
Company has not issued debt convertible into equity securities of the Company since July 2019 and does not currently intend to issue
any additional instruments convertible into the equity securities of the Company.
Item
8.01 Other Events.
On
August 27th, 2021 Regen Biopharma, Inc. (the “Company”) filed its quarterly report on Form 10-Q for the period
ended June 30, 2021. As of the date of that filing the Company is no longer delinquent with regard to reporting obligations under the
Securities and Exchange Act of 1934.
Item
8.01 Other Events.
The
Company has not issued debt convertible into equity securities of the Company since July 2019 and does not currently intend to issue
any additional instruments convertible into the equity securities of the Company.
With
regard to the remaining convertible debt outstanding ( “Remaining Notes”) it is the Company’s intent to enter into
negotiations with the remaining noteholders to settle such obligations under such terms and conditions as to eliminate or severely limit
potential dilution resulting from conversion of the Remaining Notes (“Settlement”).
No
assurances can be provided that a Settlement by and between the Company and any or all holders of the Remaining Notes will be executed
or, in the event a Settlement by and between the Company and any or all holders of the Remaining Notes is executed, such Settlement will
be on terms and conditions favorable to the Company.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
REGEN BIOPHARMA,
INC.
|
|
|
|
|
Dated: August 31, 2021
|
By: /s/
David Koos
|
|
|
David Koos
|
|
|
Chief Executive Officer
|
Regen Biopharma (PK) (USOTC:RGBP)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Regen Biopharma (PK) (USOTC:RGBP)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
